Research Analysts Offer Predictions for Halozyme Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities research analysts at Zacks Research raised their Q1 2025 earnings per share estimates for shares of Halozyme Therapeutics in a research report issued on Monday, September 23rd. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $0.93 per share for the quarter, up from their previous estimate of $0.92. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.71 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.40 EPS, Q2 2026 earnings at $1.48 EPS and FY2026 earnings at $5.90 EPS.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $65.00 price target on shares of Halozyme Therapeutics in a research report on Friday, September 13th. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Piper Sandler downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $48.00 to $51.00 in a research note on Friday, June 7th. The Goldman Sachs Group boosted their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Finally, Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, June 7th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Halozyme Therapeutics Stock Up 1.9 %

Shares of NASDAQ:HALO opened at $56.95 on Wednesday. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. The firm has a 50 day simple moving average of $58.61 and a 200-day simple moving average of $49.57. The company has a market capitalization of $7.25 billion, a PE ratio of 23.53, a P/E/G ratio of 0.56 and a beta of 1.28. Halozyme Therapeutics has a twelve month low of $32.83 and a twelve month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.18. The firm had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The firm’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.68 earnings per share.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently modified their holdings of HALO. Dimensional Fund Advisors LP raised its position in Halozyme Therapeutics by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock worth $59,622,000 after acquiring an additional 145,879 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $473,000. Norges Bank purchased a new stake in Halozyme Therapeutics during the fourth quarter worth about $44,935,000. Corient Private Wealth LLC boosted its holdings in Halozyme Therapeutics by 17.2% during the fourth quarter. Corient Private Wealth LLC now owns 21,881 shares of the biopharmaceutical company’s stock worth $809,000 after buying an additional 3,206 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV acquired a new position in Halozyme Therapeutics during the fourth quarter worth about $236,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares in the company, valued at $834,836.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 9,881 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the sale, the director now owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Nicole Labrosse sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total value of $269,650.00. Following the transaction, the chief financial officer now owns 15,480 shares in the company, valued at approximately $834,836.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 84,881 shares of company stock worth $4,932,284. 2.40% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.